Wexford Capital LP Acquires New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Wexford Capital LP acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 14,000 shares of the biopharmaceutical company's stock, valued at approximately $421,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Clearbridge Investments LLC purchased a new stake in TG Therapeutics in the 4th quarter valued at approximately $55,237,000. Raymond James Financial Inc. acquired a new position in TG Therapeutics during the fourth quarter worth $14,508,000. Braun Stacey Associates Inc. purchased a new position in TG Therapeutics in the fourth quarter worth $13,328,000. Norges Bank acquired a new stake in TG Therapeutics in the fourth quarter valued at $12,085,000. Finally, Penn Capital Management Company LLC acquired a new stake in TG Therapeutics in the fourth quarter valued at $10,577,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on TGTX shares. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $40.80.

TG Therapeutics Price Performance

NASDAQ:TGTX traded up $0.37 during mid-day trading on Friday, hitting $34.61. 761,584 shares of the company's stock traded hands, compared to its average volume of 2,978,848. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm's 50 day simple moving average is $38.24 and its 200 day simple moving average is $34.16. TG Therapeutics, Inc. has a 1 year low of $15.16 and a 1 year high of $46.48. The company has a market cap of $5.49 billion, a PE ratio of -346.08 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. During the same period last year, the company earned ($0.07) EPS. The firm's revenue for the quarter was up 90.4% on a year-over-year basis. Sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.